BioInvent Q4 2022: Focusing on Subcutaneous BI-1206 - Redeye

Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new subcutaneous version of the main candidate BI-1206, which should be free of some of the side effects of the intravenous version.

Länk till analysen i sin helhet: https://www.redeye.se/research/883359/bioinvent-q4-2022-focusing-on-subcutaneous-bi-1206?utm_source=finwire&utm_medium=RSS